Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Common Stock · Q3 FY2026 · quarter ended Sep 2026

Common stock rises 25.4% from a year ago

Common stock stood at $74K at the end of Q3 FY2026, up 25.4% from a year earlier and up 1.4% from the prior quarter. Over 3 fiscal years it compounded at +289.3% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +25.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$74K+1.4% QoQ
Last fiscal yearDec 2025
$59K+20.4% YoY
Year agoSep 2025
$59K+25.4% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.4%——
1 year+20.4%——
3-year CAGR+289.3%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
59K USD
Year-over-year change
+20.4%
4-year CAGR
+177.1%

Common Stock vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's Sep 2026 common stock of $74K is the 5th highest of the 11 companies compared; the peer median is $16K.
  • Its year-over-year change of +25.4% is the 3rd highest of 11, against a peer median of +10.1%.
  • Common stock amounts to 0.0% of total assets for ELVN, versus a peer median of 0.0%.
ELVN Competitors Peer median
Common Stock for ELVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NUVBNuvation Bio Inc.Jun 2026$1.43B +2.4%+15.3%192.0%
EXELExelixis, Inc.Jul 2026$249K -7.8%-6.8%0.0%
RLAYRelay Therapeutics, Inc.Jun 2026$211K +25.6%+11.6%0.0%
INCYIncyte CorporationJun 2026$201K +3.6%-3.9%0.0%
ELVNEnliven Therapeutics, Inc.Sep 2026$74K +25.4%+289.3%0.0%
RVMDRevolution Medicines, Inc.Jun 2026$21K +16.7%+28.3%0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$11K +57.1%+30.1%0.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$9K +0.0%+8.7%0.0%
TYRATyra Biosciences, Inc.Mar 2026$6K +20.0%+7.7%0.0%
CGEMCullinan Therapeutics, Inc.Mar 2026$6K +0.0%+6.3%0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$5K +25.0%—0.0%
Peer median (excluding ELVN) $16K+10.1%+8.7%0.0%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents110.02M75.54M100.14M124.12M98.9M
Short-term Investments00153.01M189.32M363.73M
Net Receivables00000
Inventory00000
Other Current Assets02.22M10.05M4.69M12.26M
Total Current Assets110.67M77.75M266.15M318.13M474.88M
Property, Plant & Equipment (Net)954K1.52M1.06M458K417K
Goodwill00000
Intangible Assets00000
Long-term Investments054K000
Tax Assets00000
Other Non-current Assets1.71M3.98M4.65M7.18M873K
Total Non-current Assets2.66M5.55M5.72M7.63M1.29M
Total Assets113.33M83.3M271.87M325.76M476.17M
Account Payables2.52M3.44M532K1.34M2.16M
Short-term Debt00000
Tax Payables00000
Deferred Revenue05.51M000
Other Current Liabilities233K320K10.36M204K4.65M
Total Current Liabilities5.75M9.72M25.89M15.92M16.57M
Long-term Debt00000
Deferred Tax Liabilities0000108K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities714K150.41M67K00
Total Non-current Liabilities714K150.41M67K0108K
Total Liabilities6.47M160.12M25.96M15.92M16.68M
Common Stock1K1K41K49K59K
Retained Earnings(45.2M)(82.86M)(154.45M)(243.47M)(347.17M)
Accumulated OCI0(149.75K)141K55K334K
Other Stockholders Equity00000
Minority Interest00000
Total Equity106.86M(76.83M)245.91M309.85M459.6M
Total Debt159K323K335K0399K
Net Debt(109.87M)(75.21M)(99.81M)(124.12M)(98.5M)

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.